PDF(Pubmed)
Abstract：
Hepatitis C virus (HCV) infection alters lysophosphatidylcholine (LPC) metabolism, enhancing viral infectivity and replication. Direct-acting antivirals (DAAs) effectively treat HCV and rapidly normalize serum cholesterol. In serum, LPC species are primarily albumin-bound but are also present in lipoprotein particles. This study aims to assess the impact of HCV eradication on serum LPC species levels in patients infected with HCV. Therefore, 12 different LPC species were measured by electrospray ionization tandem mass spectrometry (ESI-MS/MS) in the sera of 178 patients with chronic HCV infections at baseline, and in 176 of these patients after therapy with DAAs. All LPC species increased at 4 and 12 weeks post-initiation of DAA therapy. The serum profiles of the LPC species were similar before and after the viral cure. Patients with HCV and liver cirrhosis exhibited lower serum levels of all LPC species, except LPC 16:1, both before and after DAA treatment. Percentages of LPC 18:1 (relative to the total LPC level) were higher, and % LPC 22:5 and 22:6 were lower in cirrhotic compared to non-cirrhotic patients at baseline and at the end of therapy. LPC species levels inversely correlated with the model of end-stage liver disease score and directly with baseline and post-therapy albumin levels. Receiver operating characteristic curve analysis indicated an area under the curve of 0.773 and 0.720 for % LPC 18:1 (relative to total LPC levels) for classifying fibrosis at baseline and post-therapy, respectively. In summary, HCV elimination was found to increase all LPC species and elevated LPC 18:1 relative to total LPC levels may have pathological significance in HCV-related liver cirrhosis.
摘要：
丙型肝炎病毒（HCV）感染改变溶血磷脂酰胆碱（LPC）代谢，增强病毒感染性和复制。直接作用的抗病毒药物（DAA）可有效治疗HCV并使血清胆固醇迅速正常化。在血清中，LPC种类主要是白蛋白结合的,但也存在于脂蛋白颗粒中。本研究旨在评估HCV根除对HCV感染患者血清LPC物种水平的影响。因此,在基线时，通过电喷雾电离串联质谱（ESI-MS/MS）在178例慢性HCV感染患者的血清中测量了12种不同的LPC物种，这些患者中有176例接受DAAs治疗后。所有LPC物种在DAA治疗开始后4周和12周时增加。在病毒治疗之前和之后，LPC物种的血清谱相似。HCV和肝硬化患者表现出所有LPC物种的血清水平较低，除了LPC16：1，DAA治疗前后。LPC18：1的百分比（相对于总LPC水平）较高，和%LPC22:5和22:6低于非肝硬化患者在基线和治疗结束时。LPC物种水平与终末期肝病模型评分呈负相关，直接与基线和治疗后白蛋白水平呈负相关。受试者工作特征曲线分析显示，对于基线和治疗后的纤维化分类，%LPC18:1（相对于总LPC水平）的曲线下面积为0.773和0.720，分别。总之,发现HCV消除会增加所有LPC种类，并且相对于总LPC水平升高的LPC18：1可能在HCV相关的肝硬化中具有病理意义。
